F. Hoffmann-La Roche Ltd: US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival

Related Keywords

Australia ,Japan ,United States ,Canada ,United Kingdom ,Switzerland ,Brazil ,America ,American ,Nathalie Meetz ,Levi Garraway ,Jon Kaspar Bayard ,Karl Mahler ,Bonnie Addario ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Sileia Urech ,Birgit Masjost ,Loren Kalm ,Patrick Barth ,Karsten Kleine ,Genentech ,World Health Organization ,Drug Administration ,Head Of Global Product Development ,Foundation For Lung Cancer ,European Medicines Agency ,Roche Group ,Pharmaceuticals Industry ,American Cancer Society ,Chief Medical Officer ,Global Product ,Real Time Oncology Review ,Programmed Death ,World Health Organization Model Lists ,Essential Medicines ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Health Organization ,Cancer Society ,What Is Lung ,Hoffmann ,Oche ,Pproves ,Tecentriq ,Adjuvant ,Treatment ,Certain ,People ,Early ,Mall ,Fell ,Young ,Dancer ,